載入中
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
一般交易時段
US$0.6131
+US$0.02 · +3.37%
盤中時間採用ET。市場資料可能有所延遲。
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
日內區間
目前US$0.6131
52週區間
目前US$0.6131
盤中時間採用ET。市場資料可能有所延遲。
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
日內區間
目前US$0.6131
52週區間
目前US$0.6131
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | — | 150.26萬 USD | 58.32萬 USD | — | — |
| 銷貨成本 | — | 936.35萬 USD | 7052 USD | 1640.23萬 USD | 27.17萬 USD |
| 毛利 | — | −786.1萬 USD | 57.62萬 USD | −1640.23萬 USD | −27.17萬 USD |
| 研究與開發 | 704.3萬 USD | 936.35萬 USD | 762.75萬 USD | 9242.25萬 USD | 2389.59萬 USD |
| 銷售、一般及管理費用 | 647.66萬 USD | 645.87萬 USD | 842.07萬 USD | 2096.98萬 USD | 1355.05萬 USD |
| 營業費用 | 1323.38萬 USD | 645.87萬 USD | 1604.81萬 USD | 9699萬 USD | 3717.47萬 USD |
| 利息收入 | 65.21萬 USD | 128.91萬 USD | 122.41萬 USD | 44.87萬 USD | 1648 USD |
| 利息支出 | — | — | — | 44.87萬 USD | — |
| 折舊和攤銷 | 2.17萬 USD | 2.23萬 USD | 7052 USD | 18.64萬 USD | 27.17萬 USD |
| 營業利益 | −1323.38萬 USD | −1431.97萬 USD | −1547.2萬 USD | −1.13億 USD | −3744.64萬 USD |
| 淨利 | −1259.96萬 USD | −1295.87萬 USD | −1428.68萬 USD | −1.13億 USD | −3653.66萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
